18FDG-PET Predicts Pharmacodynamic Response to OSI-906, a Dual IGF-1R/IR Inhibitor, in Preclinical Mouse Models of Lung Cancer

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Clinical Cancer Research

• Publication date

  2011-01-21

• Fields of study

  Medicine

• Identifiers
  DOI 10.1158/1078-0432.CCR-10-2274PMID 21257723PMCID PMC3122480
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Compensatory Insulin Receptor (IR) Activation on Inhibition of Insulin-Like Growth Factor-1 Receptor (IGF-1R): Rationale for Cotargeting IGF-1R and IR in Cancer

  2010cited by this paper
• Volume of Preclinical Xenograft Tumors Is More Accurately Assessed by Ultrasound Imaging Than Manual Caliper Measurements

  2010cited by this paper
• Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation

  2009cited by this paper
• Imaging Biomarkers Predict Response to Anti-HER2 (ErbB2) Therapy in Preclinical Models of Breast Cancer

  2009cited by this paper
• Insulin receptor isoforms and insulin receptor/insulin-like growth factor receptor hybrids in physiology and disease.

  2009influential reference
• Discovery of OSI-906: a selective and orally efficacious dual inhibitor of the IGF-1 receptor and insulin receptor.

  2009cited by this paper
• Effective Use of PI3K and MEK Inhibitors to Treat Mutant K-Ras G12D and PIK3CA H1047R Murine Lung Cancers

  2008cited by this paper
• The biology of cancer: metabolic reprogramming fuels cell growth and proliferation.

  2008cited by this paper
• Molecular Imaging of Therapeutic Response to Epidermal Growth Factor Receptor Blockade in Colorectal Cancer

  2008cited by this paper
• Brick by brick: metabolism and tumor cell growth.

  2008cited by this paper
• Is cancer a disease of abnormal cellular metabolism? New angles on an old idea

  2008cited by this paper
• Tumor cell metabolism: cancer's Achilles' heel.

  2008cited by this paper
• Reproducibility of 18F-FDG microPET Studies in Mouse Tumor Xenografts

  2007cited by this paper
• A novel, potent, and selective insulin-like growth factor-I receptor kinase inhibitor blocks insulin-like growth factor-I receptor signaling in vitro and inhibits insulin-like growth factor-I receptor–dependent tumor growth in vivo

  2007influential reference
• Tumor-Specific Positron Emission Tomography Imaging in Patients: [18F] Fluorodeoxyglucose and Beyond

  2007cited by this paper
• Positron emission tomography as an imaging biomarker.

  2006cited by this paper
• Impact of animal handling on the results of 18F-FDG PET studies in mice.

  2006cited by this paper
• Involvement of insulin-like growth factor-I in the control of glucose homeostasis.

  2006cited by this paper
• IGF1R signalling and its inhibition.

  2006cited by this paper
• Progress and Promise of FDG-PET Imaging for Cancer Patient Management and Oncologic Drug Development

  2005cited by this paper
• Akt Stimulates Aerobic Glycolysis in Cancer Cells

  2004cited by this paper
• The insulin-like growth factor system and cancer.

  2003cited by this paper
• The IGF‐1 receptor in cancer biology

  2003cited by this paper
• High expression levels of insulin-like growth factor-I receptor predict poor survival among women with clear-cell renal cell carcinomas.

  2002cited by this paper
• Response: More About: Prospective Study of Colorectal Cancer Risk in Men and Plasma Levels of Insulin-Like Growth Factor (IGF)-I and IGF- Binding Protein-3

  1999cited by this paper
• Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3.

  1999cited by this paper
• Plasma levels of insulin-like growth factor-I and lung cancer risk: a case-control analysis.

  1999cited by this paper
• Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study.

  1998cited by this paper
• Circulating concentrations of insulin-like growth factor-I and risk of breast cancer.

  1998cited by this paper

• Epigallocatechin‐3‐Gallate Attenuates Benign Prostatic Hyperplasia Development via Regulating Firmicutes to Inhibit Gastric Secretion of Insulin‐Like Growth Factor‐1

  2025cites this paper
• Comprehensive analysis of telomere and aging-related signature for predicting prognosis and immunotherapy response in lung adenocarcinoma

  2025cites this paper
• Role of Insulin-like Growth Factor-1 Receptor in Tobacco Smoking-Associated Lung Cancer Development

  2024cites this paper
• Catalytic activities of wild‐type C. elegans DAF‐2 kinase and dauer‐associated mutants

  2024cites this paper
• LncRNA‐HOTAIRM1 promotes aerobic glycolysis and proliferation in osteosarcoma via the miR‐664b‐3p/Rheb/mTOR pathway

  2023cites this paper
• Emerging Role of IGF-1 in Prostate Cancer: A Promising Biomarker and Therapeutic Target

  2023cites this paper
• Preclinical evaluation of Insulin-like growth factor receptor 1 (IGF1R) and Insulin Receptor (IR) as a therapeutic targets in triple negative breast cancer

  2023cites this paper
• Biochemical characterization of the Drosophila insulin receptor kinase and longevity‐associated mutants

  2023cites this paper
• Signaling-induced systematic repression of miRNAs uncovers cancer vulnerabilities and targeted therapy sensitivity

  2023cites this paper
• Deaminative Cyclization of Tertiary Amines for the Synthesis of 2-Arylquinoline Derivatives with a Nonsubstituted Vinylene Fragment.

  2022cites this paper
• Pediatric Molecular Imaging

  2021cites this paper
• Tyrosine Kinase Inhibitors and Everolimus Reduce IGF1R Expression in HPV16-positive and -negative Squamous Cell Carcinoma

  2020cites this paper
• Preclinical Applications of Multi-Platform Imaging in Animal Models of Cancer

  2020cites this paper
• Insulin-like growth factor 1-induced enolase 2 deacetylation by HDAC3 promotes metastasis of pancreatic cancer

  2020cites this paper
• Antitumor effect of insulin‐like growth factor‐1 receptor inhibition in head and neck squamous cell carcinoma

  2020cites this paper
• Below the Surface: IGF-1R Therapeutic Targeting and Its Endocytic Journey

  2019cites this paper
• Pharmacological Blockade of ASCT2-dependent Glutamine Transport Leads To Anti-tumor Efficacy in Preclinical Models

  2017cites this paper
• Randomised Phase 2 study of maintenance linsitinib (OSI-906) in combination with erlotinib compared with placebo plus erlotinib after platinum-based chemotherapy in patients with advanced non-small cell lung cancer

  2017cites this paper
• Role of Ezrin in Colorectal Cancer Cell Survival Regulation

  2017cites this paper
• Inhibiting IGF-1R attenuates cell proliferation and VEGF production in IGF-1R over-expressing EGFR mutant non-small cell lung cancer cells

  2017cites this paper
• How PET/MR Can Add Value for Children with Cancer

  2017cites this paper
• Non-Invasive Glutamine PET Reflects Pharmacological Inhibition of BRAFV600EIn Vivo

  2017cites this paper
• Phase 2 Study of Erlotinib in Combination With Linsitinib (OSI‐906) or Placebo in Chemotherapy‐Naive Patients With Non–Small‐Cell Lung Cancer and Activating Epidermal Growth Factor Receptor Mutations

  2017cites this paper
• Metabolic Imaging to Assess Treatment Response to Cytotoxic and Cytostatic Agents

  2016cites this paper
• A Randomized Phase II Study of Linsitinib (OSI-906) Versus Topotecan in Patients With Relapsed Small-Cell Lung Cancer

  2016cites this paper
• Mass balance, pharmacokinetics, and metabolism of linsitinib in cancer patients

  2016cites this paper
• Insulin-IGF signaling affects cell transformation in the BALB/c 3T3 cell model

  2016cites this paper
• Pharmacodynamic Biomarker Development for PI3K Pathway Therapeutics

  2016cites this paper
• Inhibition of p70S6K1 Activation by Pdcd4 Overcomes the Resistance to an IGF-1R/IR Inhibitor in Colon Carcinoma Cells

  2015cites this paper
• The Role of the Insulin/IGF System in Cancer: Lessons Learned from Clinical Trials and the Energy Balance-Cancer Link

  2015cites this paper
• Radiolabeled probes targeting tyrosine-kinase receptors for personalized medicine.

  2014cites this paper
• Inhibition of p 70 S 6 K 1 Activation by Pdcd 4 Overcomes the Resistance to an IGF-1 R / IR Inhibitor in Colon Carcinoma Cells

  2014cites this paper
• Optically Based Rapid Screening Method for Proven Optimal Treatment Strategies Before Treatment Begins

  2014cites this paper
• Repositioning of Tyrosine Kinase Inhibitors as Antagonists of ATP-Binding Cassette Transporters in Anticancer Drug Resistance

  2014cites this paper
• Effects of the antitumor drug OSI-906, a dual inhibitor of IGF-1 receptor and insulin receptor, on the glycemic control, β-cell functions, and β-cell proliferation in male mice.

  2014cites this paper
• Advances in targeting insulin-like growth factor signaling pathway in cancer treatment.

  2014cites this paper
• Oridonin inhibits mTOR signaling and the growth of lung cancer tumors

  2014cites this paper
• AWARD NUMBER: W81XWH-13-1-0194 TITLE: Optically Based Rapid Screening Method for Proven Optimal Treatment Strategies Before Treatment Begins PRINCIPAL INVESTIGATOR:

  2014cites this paper
• Insulin/IGF-I Signaling Pathways Enhances Tumor Cell Invasion through Bisecting GlcNAc N-glycans Modulation. An Interplay with E-Cadherin

  2013cites this paper
• Insulin-like growth factor-1 receptor (IGF1R) as a novel target in chronic lymphocytic leukemia.

  2013cites this paper
• Development of PI3K inhibitors: lessons learned from early clinical trials

  2013cites this paper
• Integrated Systems and Technologies Optical Metabolic Imaging Identi fi es Glycolytic Levels , Subtypes , and Early-Treatment Response in Breast Cancer

  2013cites this paper
• Insulin receptor (IR) and insulin-like growth factor receptor 1 (IGF-1R) signaling systems: novel treatment strategies for cancer

  2013cites this paper
• 3′-Deoxy-3′-18F-Fluorothymidine PET Predicts Response to V600EBRAF-Targeted Therapy in Preclinical Models of Colorectal Cancer

  2013cites this paper
• Recent advancements in small molecule inhibitors of insulin-like growth factor-1 receptor (IGF-1R) tyrosine kinase as anticancer agents.

  2013cites this paper
• LYMPHOID NEOPLASIA Insulin-like growth factor-1 receptor ( IGF 1 R ) as a novel target in chronic lymphocytic leukemia

  2013cites this paper
• In vivo analysis of insulin-like growth factor type 1 receptor humanized monoclonal antibody MK-0646 and small molecule kinase inhibitor OSI-906 in colorectal cancer

  2013cites this paper
• Optical metabolic imaging identifies glycolytic levels, subtypes, and early-treatment response in breast cancer.

  2013cites this paper
• Assessment of Response to Therapy

  2012cites this paper
• MicroRNA-497 targets insulin-like growth factor 1 receptor and has a tumour suppressive role in human colorectal cancer

  2012cites this paper
• Pharmacodynamic Modelling of Biomarker Data in Oncology

  2012cites this paper
• Current world literature.

  2012cites this paper
• A kinome-wide screen identifies the insulin/IGF-I receptor pathway as a mechanism of escape from hormone dependence in breast cancer.

  2011cites this paper
• Dual Targeting of the Insulin-Like Growth Factor and Collateral Pathways in Cancer: Combating Drug Resistance

  2011cites this paper
• Current status of robotic thyroidectomy and neck dissection using a gasless transaxillary approach

  2011cites this paper
• Targeting apoptosis in cancer cells : improving TRAIL death receptor signaling

  2011cites this paper